TNDM Tandem Diabetes: Debts to Book Capitalization

Corporate company logo of Tandem Diabetes Care Inc (TNDM)

The price action of Tandem Diabetes Care (TNDM), whose metrics are recorded at 5.51, demonstrates a struggle for leadership in the diabetes management systems segment amid the threat of autonomous organ development. Revenue growth is currently fueled by global demand for compact Mobi pumps, despite the impact of GLP-1 drugs. However, international trade disputes and logistical disruptions in Asia could limit the expansion of the company's electronics.

Tandem Corp - TNDM Debts to Net Assets (period 07/04/2022 - 10/30/2026)
Original product of Tandem Diabetes Care Inc

The long-term reliability of Tandem Diabetes Care (TNDM) is determined by the balance between borrowed funds and equity, where the percentage of debt participation in balance sheet capital measures the degree of financial leverage and the risk of liquidity loss. The trend of this ratio confirms the issuer's high resilience, as stable demand for medical devices isolates the company's capital structure from macroeconomic shocks and market volatility.

Direct competitors

Debts to Book Capitalization BSX (Boston Scientific)|edwards.com (EW) - Debts to Book Value|ResMed - Debts to Book Capitalization|Insulet Corp (PODD) - Debt to Book Value|ZBH: Debts to Book Capitalization|COO - Debts to Net Assets|ALGN (Align Technology, Inc.) - Debts to Book Capitalization|Debts to Book Capitalization globusmedical.com|Debt to Book Capitalization Ratio TransMedics Organ Care System (TMDX)|Debt to Book Capitalization Ratio ATEC (Alphatec Holdings)|Debts to Book Capitalization AORT (Artivion Inc)|Debts to Net Assets Enovis Inc. (ENOV)|IART: Debt to Book Value|Debts to Book Capitalization Ratio ESTA|BBNX: Debts to Book Capitalization|Debts to Book Value IRADIMED Corp (IRMD)|EMBC (Embecta Inc.) - Debts to Book Capitalization|Debt to Book Value Ratio AXGN (Axogen Surgical)|Debt to Book Value SIBN (SI-BONE, Inc.)|OFIX (orthofix.com) - Debt to Net Assets Ratio|Debt to Book Capitalization Ratio Bioventus BVS|KIDS - Debt to Book Value|Treace Medical - Debts to Book Capitalization|Debts to Book Value Strata Medical|CARL: Debts to Book Capitalization|Debt to Book Value Ratio RXST|CLPT (ClearPoint Neuro Inc.) - Debts to Book Capitalization|Stereotaxis Inc (STXS) - Debts to Net Assets|Debts to Book Capitalization STIM|Debt to Book Value Sight Sciences Inc SGHT|Debts to Book Capitalization OBIO (Orchestra BioMed, Inc.)|Debts to Book Capitalization Anika Therapeutics Inc. ANIK|NSPR - Debt to Book Capitalization Ratio|ZJYL: Debt to Book Capitalization Ratio|VANI (vivani.com) - Debt to Book Value|Xtant Medical - Debt to Net Assets Ratio|NMTC (NeuroOne Medical Technologies) - Debts to Book Capitalization|Debts to Book Value Modular Med MODD|Debt to Book Capitalization Ratio Myomo (MYO)|Envoy Medical Inc. (COCH) - Debt to Net Assets|Vivos Therapeutics, Inc - Debt to Book Value|Debts to Book Capitalization enVVeno Corp NVNO|SINTX Technologies - Debts to Book Capitalization|Debts to Net Assets tenonmed.com TNON|Lifeward (LFWD) - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio AMIX (Autonomix Medical)|Debt to Book Capitalization Ratio INVO Bioscience, Inc.|Debt to Book Value Bone Biologics Inc (BBLG)|Debts to Book Capitalization AXNX|BIOL - Debts to Book Value|Debt to Book Capitalization Ratio Dynatronics DYNT|FNA: Debt to Book Value Ratio|INVO: Debt to Book Value